12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa

Parkinson's Disease Clinical Trial

Official title:

A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of 40 mg/Day KW-6002 as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00456586
• Other study ID #: 6002-US-005
• Status: Completed
• Phase: Phase 2
• Start date: April 2002
• Est. completion date: June 2003

Study information

• Verified date: April 2024
• Source: Kyowa Kirin Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Description:

A 12-week, double-blind, placebo-controlled, multicenter, randomized study designed to evaluate the safety and efficacy of 40 mg/day istradefylline compared with placebo in subjects with OFF phenomena advanced PD who were treated with levodopa/carbidopa.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 180
• Est. completion date: June 2003
• Est. primary completion date: May 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

1. United Kingdom Parkinson's Disease Society brain bank diagnostic criteria (step 1 and 2).

2. Modified Hoehn and Yahr Scale II-IV in the OFF state.

3. Treated with levodopa/carbidopa for 1 year with a stable regimen for 4 weeks prior to randomization.

4. Taking at least 4 doses of levodopa (3 doses if at least 2 doses containing slow release formulation) per day with predictable end of dose wearing off.

5. Successfully completed Parkinson's disease patient diary training with at least 120 minutes of OFF time per day.

6. Stable regimen of other antiparkinson's disease medications for at least 4 weeks prior to randomization.

7. At least 30 years of age and able to give written informed consent.

Exclusion Criteria:

1. Treatment with liquid levodopa/carbodopa within 4 weeks of randomization.

2. Treatment with MAO inhibitors except selegiline.

3. Treatment with centrally acting dopamine antagonists within 3 months (6 months for depot preparations), e.g., antipsychotic neuroleptics, metoclopramide, buspirone, amoxapine.

4. Neurosurgical surgery for Parkinson's disease.

5. Atypical parkinsonism or secondary parkinsonism variants.

6. Diagnosis of cancer or evidence of continued cancer within 5 years of enrollment or clinically significant illness of any organ system (e.g., ALT or AST > 1.5 times the upper limit of normal).

7. Mini-Mental Status Examination score of 25 or less.

8. History of drug or alcohol abuse or dependence within 2 years.

9. History of psychotic illness or seizures.

10. Current clinically relevant depression disorder.

11. History of neuroleptic malignant syndrome.

12. Pregnant or lactating females. Women of child-bearing potential must use reliable method of contraception.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• KW-6002 (istradefylline)

Locations

Country	Name	City	State
United States	Contact Kyowa Pharmacuetical Inc.	Princeton	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Kyowa Kirin, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and efficacy of 40 mg/day istradefylline for reducing OFF time in subjects with Parkinson's disease (PD) treated with levodopa/carbidopa.
Secondary	To establish the efficacy of 40 mg/day istradefylline for reducing motor symptoms and improving activities of daily living (ADL) in subjects with advanced PD treated with levodopa/carbidopa.